Resilience to Antibiotic-induced Obesogenic Microbiota: Discovering Mechanism of Microbiota Modulation

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age2+
SponsorTurku University Hospital

About this trial

The aim is to study whether the microbiota of children who are exposed to antibiotics at birth could be modified by synbiotic supplement and thereby reduce the risk of obesity, chronic diseases and respiratory tract infections. A total of 125 mother-child pairs will be recruited in this randomized, double-blind, placebo-controlled study. Infants are randomized to receive either a synbiotic supplement or a placebo for 2 months, after which their growth and morbidity will be monitored at the research clinic for 2 years.

Eligibility criteria

Qualifiers

None

Disqualifiers

Chorioamnionitis

Pre-eclampsia and hepatogestosis

Suspected malformation or serious condition of the foetus and neonates

Serious infection or other conditions not permitting breast milk feeding

Trial design

Treatments tested in this trial

  • Synbiotic Supplement
  • Placebo

Treatment groups

125 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Turku University Hospital

Lead sponsor

Lallemand Health Solutions

Collaborator